Low procalcitonin, community acquired pneumonia, and antibiotic therapy

The Lancet Infectious Diseases

Volumn 18, Issue 5, 2018, Pages 496-497

  Kamat, Ishan S ^a   Ramachandran, Vignesh ^a   Eswaran, Harish ^a   Abers, Michael S ^b   Musher, Daniel M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROCALCITONIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE EXACERBATION; EMERGENCY WARD; HUMAN; INTENSIVE CARE UNIT; LETTER; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS PNEUMONIA; COMMUNITY ACQUIRED INFECTION; PNEUMONIA; RESPIRATORY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA; PROCALCITONIN; RESPIRATORY TRACT INFECTIONS;

EID: 85045559967     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(18)30215-9     Document Type: Letter

References (5)

1. Schuetz, P, Wirz, Y, Sager, R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis 18 (2018), 95–107.
2. Fontela, PS, Papenburg, J, Procalcitonin and antibiotic use: imperfect, yet effective. Lancet Infect Dis 18 (2018), 11–13.
3. de Jong, E, van Oers, JA, Beishuizen, A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16 (2016), 819–827.
4. Bloos, F, Trips, E, Nierhaus, A, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Intern Med 176 (2016), 1266–1276.
5. Bouadma, L, Luyt, CE, Tubach, F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375 (2010), 463–474.